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Role of the renin-angiotensin system on the renal functional reserve in
renal transplant recipients. To determine the renal functional reserve in
renal transplant recipients, we measured the glomerular filtration rate
by inulin clearance and the renal plasma flow by PAH clearance before
and during an amino acid infusion (Totamine, 6 to 8 mg/kg/mm for 90 to
120 mm) in 18 transplanted patients with stable renal function. To test
the role of the renin-angiotensin system on the renal functional reserve,
we performed a crossover placebo-controlled randomized trial of acute
blockade of the renin-angiotensin system by injection of perindoprilat (2
mg iv.), an inhibitor of angiotensin converting enzyme before amino
acid infusion, each patient being studied twice at seven day intervals.
Amino acid infusion induced a time-dependent increase in the glomer-
ular filtration rate (P = 0.04), whether or not the renin-angiotensin
system was blocked. Maximal increases were from 49.1 4.1 to 58.9
5.4, mean SE (18.5%), in control conditions and from 52.4 5.6 to
62.1 5.5 ml/min/1 .73 m2 (19.7%) after perindoprilat. The increase in
glomerular filtration rate was less pronounced in patients taking cyclo-
sporin A than in patients treated with steroid and azathioprine. Amino
acid infusion also induced a significant and time-dependent increase
(15.2 to 20.2%) in the renal plasma flow (P < 0.01) whether or not
perindoprilat had been given. Furthermore, perindoprilat alone in-
creased renal plasma flow by 13.6%, and this effect seemed additive
with that of amino acids. Perindoprilat injection decreased filtration
fraction (from 0.20 0.01 to 0.19 0.01). This parameter returned to
basal values after amino acid infusion (0.20 0.01). Amino acid
infusion decreased renal vascular resistances as did perindoprilat alone.
After permndoprilat administration, renal vascular resistances further
decreased during amino acid infusion (P = 0.03). These results demon-
strate that renal transplant recipients possess a renal functional reserve
of which the mobilization is not inhibited in acute experiments by
blockade of the renin-angiotensin system.
A long-term protein-rich diet has been shown to increase
glomerular blood flow and mean glomerular capillary pressure,
and to accelerate the appearance of glomeruloscierosis in
various models of reduced renal mass [1]. In humans, short-
term experiments demonstrated that an oral protein meal [2—4]
or an amino acid (AA) infusion [5] increased renal blood flow
(RBF) and glomerular filtration rate (GFR) and could be used to
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measure the renal functional reserve (RFR) defined as the
difference between the maximal and the basal GFR values.
Renal transplantation in humans represents a typical model of
prolonged reduction of renal mass. Although renal graft sur-
vival has been improved with the use of new immunosuppres-
sive agents, some patients experience a progressive loss of
renal function due to rejection, hypertension and/or progressive
glomerular sclerosis [6]. The latter may be secundary to gb-
merular hypertension and hyperfiltration that accompany im-
portant reduction in renal mass [7]. In renal transplanted
patients some studies have shown that the renal functional
reserve can be recruited by protein loading [8—Il]. However,
despite normal or subnormal creatinine levels, some of these
patients with systemic hypertension [11] or taking cyclosporin
A [9] have been shown to have low or no renal functional
reserve, suggesting that they had permanent hyperfiltration or
renal vasoconstriction. During hyperfiltration induced by pro-
tein loading, there is an increase in afferent glomerular blood
flow and in glomerular capillary pressure [12]. The exact
mechanism of these changes remains unclear and could involve
an alteration of the tubuloglomerular feedback [13] and/or
changes in the secretion of prostaglandins [14], glucagon [14—
17], growth hormone [181, or endothelial-derived relaxing factor
[191. Controversial results were reported concerning the role of
the renin-angiotensin system. In the rat, a protein-rich diet
increases plasma renin activity [20, 211 but decreases the
vasopressive response to exogenous angiotensin II, probably
through an increase in prostaglandin synthesis. In humans,
activation of the renin-angiotensin axis by salt depletion pre-
vents the mobilization of the renal functional reserve during AA
infusion, and this inhibition is reversed by angiotensin convert-
ing enzyme inhibition [221. These results suggest that angioten-
sin II inhibits the mobilization of the renal functional reserve.
On the other hand, it has been shown in the rat that chronic
administration of an angiotensin converting enzyme inhibitor
inhibits the mobilization of the renal functional reserve [23] and
prevents glomerular sclerosis in experimental models of renal
mass reduction [7]. These results would rather suggest that
angiotensin II plays a role in hyperfiltration and associated
glomerular lesions.
In order to investigate the role of the renin-angiotensin axis in
hyperfiltration induced by protein loading in renal transplant
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Table 1. Patient characteristics
Patient
no.
Age
years
Time since
transplantation
months
Antihypertensive
treatment
Serum
creatinine
juno//liter
Proteinuria
g124 hr Treatment Cyclosporin A
1 30 25 b,a,h 140 0.44 triple yes
2 40 14 none 68 0 triple yes
3 34 29 b 200 0.58 triple yes
4 39 62 b 130 0 double no
5 28 31 b 210 0 triple yes
6 45 56 t,b 130 0.28 triple yes
7 45 34 b,h 70 2.46 triple yes
8 46 80 none 100 0.24 double no
9 46 73 none 85 0 double no
10 37 48 none 110 0 triple yes
11 33 9 b 90 0.26 triple yes
12 58 18 c 140 0.34 triple yes
13 40 35 none 125 0.32 triple yes
14 44 240 none 66 0.22 double no
15 58 85 none 84 0.32 triple yes
16 34 71 none 90 0 double no
17
18
44
24
71
II
none
none
120
129
0.24
0
triple
double
yes
yes
Abbreviations are: a, diuretic; b, beta blocking agent; c, calcium channel inhibitor; h, hydralazine; t, thiazidic.
recipients, we performed a randomized crossover placebo-
controlled trial of acute blockade of angiotensin converting
enzyme during AA infusion. In these patients, the results show
that ACE inhibition does not prevent, but even potentiates the
increase in GFR induced by AA infusion.
Methods
Patients
Between July 1989 and June 1990, eighteen patients who had
received a cadaveric renal transplant were included in the
study, after they had signed an informed consent. The protocol
was approved by the Ethical Committee of the Faculté de
Médecine Saint Antoine (Paris, France). The main data con-
cerning the patients are given in Table 1. Criteria for patients
included a stable renal function for at least two months before
entry with a plasma creatinine level lower than or equal to 210
jimol/liter and who were not treated by an ACE inhibitor. Renal
arterial stenosis was eliminated on clinical and echographic-
Doppler examinations. Immunosuppressive therapy (usually
triple therapy) was unchanged during the entire study, and no
patient received nonsteroidal anti-inflammatory agents. All
received 100 mg/day aspirin as a routinely administered anti-
platelet agent. Patients were asked not to modify their salt and
protein diet during the study to reduce individual variations.
This was controlled by measurements of sodium and urea
urinary excretion. Urinary excretions of sodium were not
different between the first and second periods (17.9 5.8 vs.
23.8 7.1 mmol!mmol creatinine, respectively, P > 0.05).
Similarly, there was no significant difference in urinary excre-
tion of urea between the first and second period (46.7 5.8 vs.
59.5 6.7 mmollmmol creatinine respectively, P > 0.05).
Study design
This was a crossover double-blind study. Each patient was
studied twice (2 periods, P1 and P2), at one week intervals and
each acted as his own control. Patients received an AA infusion
with or without previous acute blockade of the renin-angioten-
sin system by intravenous injection of sodium perindoprilat, an
angiotensin converting enzyme inhibitor [24]. Patients were
randomized to receive, in a double-blind trial, either placebo for
the first period and perindoprilat for the second period or
vice-versa. Each period consisted of three successive phases
(control, placebo or perindoprilat, AA infusion) and each phase
was divided into three time intervals of 30 minutes.
Before starting the first phase of each period, patients had
been fasting for at least 12 hours except that they took their
immunosuppressive treatment including cyclosporin A, and an
hydric charge of 200 ml distilled water at 8 a.m. Antihyperten-
sive treatment was stopped the day before the study. Patients
remained supine except to void. At 9 a.m. an intravenous
catheter was inserted in each arm for perfusion on one side and
blood sampling on the other. After basal urine and blood
samples were taken, inulin (150 mg/liter of extracellular water
estimated to 20% of body wt) and paraaminohippuric acid (15
mg/liter of diffusion volume of PAH estimated to 40% of body
wt) were given as loading doses followed by a continuous
infusion calculated to obtain constant plasma levels of inulin
and PAH. After the first phase of 3 x 30 minutes, used to
measure basal values of glomerular filtration rate (GFR) and
renal plasma flow (RPF), placebo or perindoprilat (2 mg) were
injected in a two-minute i.v. infusion, and GFR and RPF were
further measured during a second phase of 3 x 30 minutes.
Then, the third phase was started consisting of an AA infusion
(Totamine, 6 to 8 mg/kg body wt/min) maintained for 90 to 120
minutes. The first five patients included in the protocol received
Totamine at a rate of 8 mg/kg body wt/min for 90 minutes. Since
two of them experienced nausea and vomiting in relation with
the AA infusion, the rate of infusion was decreased to 6
mg/kg/mm for 120 minutes in the 13 remaining patients. Tota-
mine composition is given in Table 2.
A week later, the second study was performed (period 2) in
the same patient. The same protocol was used except for
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Table 2. Amino acid composition of totamine
Amino acid mg/100 ml
L-Isoleucine 556.6
L-Leucine 800
L-Lysine 480
L-Methionine 300
L-Phenylalanine 666.6
L-Threonine 293
L-Tryptophane 146.6
L-Valine 605
L-Arginine 800
L-Histidine 250
L-Alanine 533
L-Aspartate 266.6
L-Cysteine 133.2
L-Glutarnate 267
L-Glycine 933.2
L-Ornithine 238
L-Proline 533.2
L-Serine 266.6
L-Tyrosine 40
placebo or perindoprilat injection depending on the randomiza-
tion.
Measurements
Sodium and potassium concentrations were measured by
flame photometry (Ii Meter 243), protein concentration by
colorimetry (Technicon RAXT), osmolality by freezing point
(Fiske Osmometer) and inulin and PAH concentrations by
colorimetry (Technicon AA II). Plasma renin activity was
determined by RIA (RIANEN 022); aldosterone and ANF were
measured according to Pham Huu Trung et al [25] and Pruzc-
zynski et al, respectively [26]. cGMP and glucagon were
measured by RIA using commercial kits from Amersham and
Pharmacia, respectively. ACE activity was measured by cob-
rimet1y [271. Normal values in our laboratory are 18.4 1.1
nmol/iiin/ml (mean SE).
Inulin clearance and PAH clearance were calculated accord-
ing to the UV/P formula. Creatinine plasma levels were deter-
mined at the beginning and at 30 minute intervals during each
phase, as were serum and urine electrolytes and glycemia.
Plasma renin activity, aldosterone, ANF, and glucagon were
measured at the end of each phase of each period. Mean arterial
pressure (MAP) was calculated by the formula: diastolic pres-
sure + 1/3 differential pressure. Systolic and diastolic pressures
were measured with a sphygmomanometer each 30 minutes
during each phase.
Calculations
GFR (inulin clearance) and RPF (PAH clearance) were
normalized to 1.73 m2 of body surface area. Filtration fraction
(FF) was calculated by the ratio GFRJRPF. Renal vascular
resistances (RVR) were estimated by the ratio MAP/RBF where
MAP is the mean arterial pressure and RBF is the renal blood
flow, calculated as RPF/(1 — Hematocrit).
Statistical analysis
Results are presented as mean SEM. Mean plasma and urine
concentrations of electrolytes and hormones of the different
phases were compared by two way analysis of variance or by
paired t-test. Linear regression analysis was used to study the
correlation between two quantitative values. Crossover three-
way analysis of variance was used to test the effect of sequence
(A factor representing the order of treatment administration for
the first and second period: placebo then perindoprilat or the
opposite), treatment (B factor for placebo or perindoprilat) and
time during each phase of each period (C factor) for the renal
functional parameters [28]. If there was no statistically signifi-
cant interaction for A x B x C and A x C as well as no
significant effect of A, B x C interaction was considered. If B x
C interaction was significant, indicating a role of perindoprilat
compared to placebo on the time-course of the parameter
studied, complementary analyses were performed for each
treatment and each time. If the treatment effect was significant,
then the differences between values at different times for each
treatment were evaluated by Neuman Keuls test. If B X C
interaction was not significant, the treatment effect and the time
effect were described and only the evolution of the parameter
under placebo conditions from both periods was considered to
evaluate the effect of time. If time effect was significant,
comparison between values were performed by the Neuman
Keuls method.
On the other hand, if A x B x C or A x C or A effect were
statistically significant, then successive analyses of variance
were performed to compare the different phases. If an interac-
tion was still found, then the first period only was used for a two
way analysis of variance followed, in case of significant time
effect, by the Neuman Keuls test to compare values at different
times.
Results
Hemodynamic parameters
As shown in Figure 1, AA infusion induced a 19.7% increase
in GFR in control conditions and a 18.5% increase in GFR in
perindoprilat conditions. This effect was time-dependent (P =
0.04). Mean GFR rose from 49.1 4.11 to the maximal value of
58.8 5.44 ml/min/1.73 m2 (P  0.05) which was observed after
60 to 90 minutes of AA infusion under placebo conditions (P =
0.006). GFR rose from 52.4 5.6 to 62.1 5.5 mllmin/1.73 m2
in perindoprilat-pretreated patients, the maximal value being
observed after 60 minutes of AA infusion. There was a signifi-
cant linear correlation between absolute increment of GFR and
the baseline GFR (y = —23.1 + 0.651 x, r = 0.547, P < 0.025,
where y is increment of GFR and x baseline GFR), indicating
that the lower was baseline GFR, the lower was the AA induced
increase in GFR. When expressed as a percentage of baseline
GFR, the increment in GFR was not correlated with GFR (r
0.19, P > 0.25). Perindoprilat per se did not significantly change
GFR in these patients. AA infusion induced a significant
increase in RPF whether or not patients had received perindop-
rilat (Fig. 1). Three-way analysis of variance indicated that this
effect was time-dependent (P 0.008) and that perindoprilat by
itself also increased significantly RPF (P = 0.004). A 15.2%
increase in RPF was observed under placebo conditions, from
244.2 19.1 to 281.3 29.3 ml/min/1.73 m2 at 90 minutes of AA
infusion. After perindoprilat administration, a 13.6% increase in
RPF was found, from 239.1 20.7 to 271.6 21.8 mllmin/l.73
m2 during the next 90 minutes, and a further increase, 20.2%
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Fig. 2. Time-course of mean arterial blood
plasma pressure (A) and of renal vascular
resistances (B) during an amino acid infusion
in renal transplanted patients with (•) or
without (0) pretreatment by an angiotensin
converting enzyme inhibitor, perindoprilat.
Means SEM are represented. *P < 0.05
300 compared to respective basal value, according
to the three-way analysis of variance
described in the Methods.
increment after AA infusion to a maximal value of 319.9 27.1
ml/min/l .73 m, was also found at 60 minutes of AA infusion.
Calculation of FF and two-way analysis of variance of the
results indicated that there was no significant changes of FF
during AA infusion whether patients had received placebo or
perindoprilat. However, perindoprilat by itself induced a small
decrease in FF from 0.20 0.01 to 0.19 0.01% which was
reversed by AA infusion inducing a time-dependent significant
variation of FF in this case (P 0.016).
As shown in Figure 2, mean arterial blood pressure did not
change significantly during the study whether or not the patients
received perindoprilat. In contrast, the renal vascular resis-
tances (RVR) were significantly modified according to treat-
ment and time. AA infusion induced a decrease in RVR that
was more pronounced when patients had received perindopri-
lat. Perindoprilat alone lowered RVR from 0.28 0.03 to 0.23
0.03 mm Hg/inllmin/1.73 m2 (P = 0.055). The treatment effect
was significant after 60 minutes of AA infusion (P = 0.031).
Hormonal and hydroelectrolytic variations
Analysis of variance indicated that there was a slight but
significant decrease in protein plasma level during AA infusion
whether or not patients had received perindoprilat (Table 3, P <
0.001). Penndoprilat alone had no effect on plasma osmolality.
Plasma renin activity was slightly but not significantly de-
creased by AA infusion under placebo conditions whereas
perindoprilat increased PRA before AA infusion. Similarly and
as expected, perindoprilat induced a rapid and profound de-
crease of serum ACE activity (P < 0.001), and AA infusion
induced a small decrease of ACE activity under placebo con-
ditions.
Aldosterone plasma levels were slightly and not significantly
increased by AA infusion, but were significantly lower after
perindopnlat compared to placebo conditions (P < 0.014).
Before AA infusion, plasma ANF levels tended to decrease
with time whether or not the patients had received perindopri-
lat. AA infusion induced a slight but not significant increase in
ANF levels under placebo conditions. A significant increase in
ANF levels was observed during AA infusion when patients
received perindoprilat (P < 0.034). No significant variation of
urinary excretion of cGMP was observed. Plasma glucagon
levels were significantly (P < 0.001) increased by AA infusion,
whether or not patients had received perindoprilat.
A posteriori, we compared patients who took cyclosporin A
to those who did not. As shown in Figure 3, patients who
received cyclosporin A (N = 13) had a lower GFR than those
who did not (N = 5). In both groups AA infusion induced a rise
in GFR, although this rise was less pronounced in patients
receiving cyclosporin A. We also compared hypertensive pa-
tients (N = 8) who were treated by antihypertensive drugs other
than converting enzyme inhibitors, and normotensive patients
(N = 10). As shown in Figure 3, AA infusion induced a rise in
GFR in both groups of patients after placebo or perindoprilat
injection.
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Fig. 1. Time-course of glomerular filtration
rate (A) and of renal plasma flow (B) in renal
transplanted patients during an aminoacid
infusion with (I) or without (0) pretreatment
by an angiotensin converting enzyme
inhibitor, perindoprilat. Means SEM are
represented. *P < 0.05, and ** < 0.01
compared to respective basal value, according
to the three-way analysis of variance
described in the Methods.
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Table 3. Laboratory measurements in renal transplanted patients during amino acid infusion with or without pretreatment with an angiotensin
converting enzyme inhibitor, perindoprilat
Treatment Basal values
After
treatment
After amino
acid infusion
Plasma
Sodium mmol/iiter Placebo
Perindoprilat
138.5 1.8
139 2.2
138.3 2
138.8 2.1
136.1 J5C
136.6 2C
Potassium mmol/liter Placebo
Perindoprilat
4.2 0.4
4.2 0.4
4.2 0.4
4.2 0.4
4.4 0.6
4.4 o.4
Proteins g/iiter Placebo 63.5 1.4 64.2 1.5 62.1 14b
Osmolality mOsm/kg
Perindopnlat
Placebo
Perindoprilat
63 1.4
292.1 1.6
291.8 1.3
63.4 1.4
291.5 1.8
291.7 1.2
61.7 1.4"
296.3 1.7"
295.2 1.4"
PRA pg/mi/hr Placebo
Perindoprilat
1488 1265
1198 740
1426 342
2138 1611
1224 640
1939 1424
Aldosterone pg/mi Placebo
Perindoprilat
68.6 17.4
72.1 22.7
108.9 26.7
37.8 5.9
146.3 34.6
40.7 7.6d
ANF pg/mi Placebo
Perindoprilat
63.8 11.1
68 10.4
51.1 8.3
48.1 6.7a
69 13.2
59.8 9.6
ACE nmoi/min/mi Placebo
Perindoprilat
15.8 1.3
15.8 1.5
15.8 1.2
0.7 0.2"
14.4 1.2
1.7 0.2"
Glucagon g/1OO ml Placebo
Perindoprilat
143 23
142 26
118 15
128 24
346 47C
342 44C
Urine
cGMP pmoi/min Placebo
Perindoprilat
682 148
550 67
504 62
462 56
636 76
693 73
Data are mean SEM. Mean values at each phase were compared by paired (-test.
a p < 0.05, b P < 0.01, P < 0.001 compared to respective basal values
d P < 0.05 compared to placebo
Discussion
This study demonstrates that in renal transplant recipients
with normal or subnormal renal function, a renal functional
reserve can be acutely mobilized by AA infusion. Acute block-
ade of the renin-angiotensin system by perindoprilat injection
does not inhibit the effect of AA infusion and even tends to
increase GFR and RPF.
Effect of AA infusion
In renal transplant recipients with subnormal plasma creati-
nine levels, we found that AA infusion was able to induce a 15
to 20% increase in mean GFR and mean RPF. Furthermore, the
absolute increase in GFR was positively correlated with the
baseline GFR, but the percentage of increase was not statisti-
cally different. Similar observations have been reported in
patients with normal kidney function, glomerulonephritis, uni-
lateral nephrectomy or large reduction in renal mass by Zuccala
et al [29]. However, in contrast with these authors who reported
a 40% increase in GFR, we found only a 20% increase in GFR
in our patients. A low response to protein loading is usually
attributed to chronic hyperfiltration and glomerular hyperten-
sion, both conditions which may lead to glomerular sclerosis [1]
and which may exist in some transplanted patients. It has been
shown that the response to AA may be decreased in the
presence of renal parenchymal injury [30, 31], systemic hyper-
tension [11], high protein diet [31] or cyclosporin A treatment
[9], conditions that are also frequently observed in transplanted
patients. Biochicchio et al found a significant but transient and
blunted increase in GFR after a high protein meal in a selected
group of hypertensive renal transplant recipients compared to
normal subjects [11]. These authors suggested that systemic
hypertension found in their patients may have induced in-
creased glomerular pressure and hyperfiltration precluding fur-
ther increase in GFR during protein load. Such an effect may
also explain in part the low percentage of GFR increase after
AA infusion that we observed. However, it has to be outlined
that, in contrast to the study by these authors, our patients had
no hypertension during the study and that this may explain why
we did not find differences in AA effects between chronic
normotensive and hypertensive patients.
Although we did not measure plasma AA concentration, it is
likely that AA infusion induces a greater increase in AA
concentration and has a more pronounced effect on GFR than
oral protein load [5, 13—15]. Furthermore, our hypertensive
patients were treated until the day before AA infusion and had
normal blood pressure during the study period. This may
explain why we did not find significant differences in the
response to AA infusion between normotensive and hyperten-
sive patients (Fig. 3). Although the magnitude of increase in
GFR was lower in patients taking cyclosporin A than in those
who received conventional immunosuppression, we found that
AA infusion was able to increase mean GFR and RPF in both
these groups of patients. This is in agreement with a previous
study which showed that a high protein meal increased blood
flow to transplanted human kidneys, even under cyclosporin A
treatment [10]. In contrast, Nunley et al [9] failed to demon-
strate an increase in GFR and in RPF in renal transplanted
patients taking cyclosporin A after an oral protein load.
The reasons for these discrepancies remain unclear but may
be related to the differences in plasma AA concentrations after
oral protein intake and i.v. AA infusion. We found a single
report of AA infusion in transplanted patients, which demon-
strated a significant increase in both GFR (22%) and RPF (19%)
in renal transplanted patients not taking cyclosporin A, but low
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or no response in patients treated by cyclosporin A [32].
However, compared to our study protocol, these authors used
a lower rate of AA infusion, lasting for two hours and in their
study the increase in GFR was observed 30 to 90 minutes after
the end of AA infusion.
The mechanisms of increase in GFR and RPF during oral or
i.v. protein loading have been extensively studied and are
related to a decrease in RVR with afferent and efferent arterio-
lar vasodilation. This explains the absence of significant
changes in filtration fraction that we observed and that has been
reported previously in nontransplanted patients [3]. Mediators
of this vasodilation are still debated, and glucagon [14-17],
prostaglandins [14] and more recently nitric oxide [19] have
been incriminated. Conversely, activation of the renin-angio-
tensin axis seems to have an inhibitory effect on the mobiliza-
tion of the renal functional reserve [221. Interestingly, renal
innervation is not required to observe an increase in blood flow
after a high protein meal as it has been reported in patients
shortly after renal transplantation [101.
As expected and previously reported in nontransplanted
patients, we found that AA perfusion induced a significant
increase in plasma glucagon level [14—17] and little variations in
PRA, plasma ANF or urinary excretion of cGMP. In normal
volunteers, meals with high or low protein content were not
found to modify plasma ANF levels suggesting that this hor-
mone does not play a major role in the protein-induced hyper-
filtration [33]. In our study, plasma ANF remained unchanged
during the three phases of the placebo period suggesting that
AA infusion did not induce fluid overload which could have
been responsible for the increase in GFR and RPF. The absence
of increase in urinary cGMP excretion can also be explained by
the constant ANF plasma levels. However, urinary cGMP was
not well correlated with ANF variations in patients with renal
failure [34]. In normal volunteers receiving AA infusion, no
variation of urinary cGMP was observed [15] but these results
do not exclude an increased glomerular generation of cGMP. A
role for EDRF which increases guanylate cyclase activity as a
potential mediator of AA-induced hyperfiltration has been
suggested. Controversial results exist concerning the role of
other vasodilatory mediators such as prostaglandins [14, 20,
22]. We did not measure these compounds. It remains possible
that steroids may have inhibited and cyclosporin A stimulated
prostaglandin synthesis in our patients as reported by others
[35]. Recently, Wada, Don and Schambelan [16] did not ob-
serve an increased urinary excretion of PGE2 and 6-keto-
PGF1a during AA infusion in humans confirming the observa-
tions of Hirschberg et a! [14]. However, the latter authors
reported a significant decrease in AA-induced hyperfiltration in
patients taking indomethacin or ibuprofen, suggesting that
prostaglandins are indeed involved in this phenomenon. A
possible explanation for this discrepancy may be that urinary
excretion of prostaglandins is not well related to glomerular or
vascular prostaglandin synthesis.
Role of the renin-angiotensin system
We also studied the role of the renin-angiotensin system in
renal hemodynamics of renal transplanted patients. We found
that acute blockade of RAS by perindoprilat injection, which
was confirmed by the striking decrease in serum ACE activity
and the subsequent increase in PRA, induced no variation of
systemic blood pressure but a significant renal vasodilation
(decreased RVR) and an increase in RPF. This suggests that
there is an intrarenal basal activation of RAS in transplanted
patients. Since GFR remained unchanged, the calculated FF
was decreased. These hemodynamic variations were previously
studied in experimental models, and it has been demonstrated
that acute blockade of angiotensin II receptors induced an
increase in the diameter of interlobular arteries and glomerular
efferent arterioles [36]. Our results also demonstrate that AA-
induced hyperfiltration is observed whether or not RAS has
been blocked and that RPF which is increased by RAS blockade
is further increased by AA infusion. These results suggest a
permissive effect of RAS blockade on hyperfiltration induced
by AA infusion. Activation of RAS by salt restriction prevents
AA-induced renal hemodynamic effects in normal volunteers
[221 indicating that high levels of renal angiotensin II may
inhibit AA-induced vasodilation. Furthermore, when salt-de-
pleted patients were treated with captopril, the hemodynamic
effects of AA infusion were restored [22]. Dopamine combined
with AA infusion has also been shown to induce an increase in
GFR in salt-depleted normal volunteers indicating that RFR can
A
B
Placebo Perindoprilat Placebo Perindoprilat
Normotensive Hypertensive
90
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E50
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30
Placebo Perindoprilat Placebo Perindoprilat
without CSA with CSA
Fig. 3. Effect of hypertension (A) and of cyclosporin A treatment (B) on
the mobilization of the renal functional reserve by an amino acid
infusion in renal transplanted patients pretreated or not with an
angiotensin converting enzyme inhibitor, perindoprilat. Symbols are:
(U)before and () after AA infusion. Means SEM are represented. p
< 0.05, "P < 0.01 compared to respective basal values, §P < 0.025
compared to values of patients without cyclosporin A, by unpaired
t-test.
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be demonstrated if appropriate antagonists of angiotensin II-
induced vasoconstriction are used [37]. Concordant results
were reported by Slomowitz, Hirschberg and Kopple [38], who
found that in diabetic patients with normal renal function,
AA-infusion induced a greater increase in GFR and RPF after
pretreatment by captopril than before. These authors failed to
demonstrate similar results in normal volunteers, and suggested
that renal angiotensin II might be increased in diabetic patients
or that captopril might have enhanced the AA-induced rise in
RPF and GFR by other mechanisms, such as increasing tissue
kinins, PGE2 or other vasoregulatory compounds. We cannot
exclude that these mechanisms were also involved in our
transplanted patients receiving perindoprilat and AA infusion.
It has to be noted that we did not find a significant variation
in PRA during AA infusion, and this is in agreement with
short-term studies, using either AA infusion or protein-rich
meal that have been reported [15, 16]. Conversely in long-term
studies, it has been shown that a protein-rich diet may increase
PRA in rats and decrease the pressor response to angiotensin II
[20, 211. This decrease has been related to secondary enhance-
ment in prostaglandin synthesis. More recently, an increase in
renin mRNA in renal cortex of rats fed a high-protein diet has
been reported [391. Long-term increase in renal angiotensin II
may have deleterious effect on the permselectivity of the
glomerular basement membrane and the glomerular structure.
Long-term treatment with ACE inhibitors also gave different
results. In a rat experimental model, Corman et a! [23] demon-
strated that post-prandial increase in GFR was inhibited by
chronic treatment with perindoprilat, an effect that might be
related to the lower blood pressure of treated rats. On the other
hand, Biochicchio et a! reported that in renal transplant recip-
ients who had hypertension, a significant but low increase in
GFR could be induced by an acute protein intake [11]. After one
to four months of treatment with an ACE inhibitor, fosinopril,
baseline mean arterial pressure was decreased, as were GFR
and proteinuria. Furthermore, an increase in GFR after protein
load was observed [11]. These long-term hemodynamic effects
of ACE inhibition are thus quite different from those that we
and others have observed in acute experiments.
In conclusion, our study demonstrates that in kidney-trans-
planted patients AA infusion is able to increase GFR and RPF.
Acute blockade of the renin-angiotensin system does not pre-
vent this effect but even increases renal vasodilation and
hyperfiltration induced by AA infusion. The short-term effects
of AA and ACE inhibition on GFR may be quite different from
that of long-term protein-rich diet and treatment with ACE
inhibitors.
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